Proton pump inhibitor on susceptibility to COVID-19 and its severity : a systematic review and meta-analysis
© 2021. Maj Institute of Pharmacology Polish Academy of Sciences..
BACKGROUND: The negative impacts of proton pump inhibitor (PPI), including the risk of pneumonia and mortality, have been reported previously. This meta-analysis aimed to address the current interest of whether the administration of PPI could increase the susceptibility and risk of poor outcome in COVID-19.
METHODS: We performed a systematic literature search from PubMed, Embase, EBSCOhost, and EuropePMC databases up until 3 December 2020. The main outcome was composite poor outcome which comprised of mortality and severe COVID-19. Severe COVID-19 in this study was defined as patients with COVID-19 that fulfill the criteria for severe CAP, including the need for intensive unit care or mechanical ventilation. The secondary outcome was susceptibility, based on cohort comparing COVID-19 positive and COVID-19 negative participants.
RESULTS: There were a total of 290,455 patients from 12 studies in this meta-analysis. PPI use was associated with increased composite poor outcome (OR 1.85 [1.13, 3.03], p = 0.014; I2 90.26%). Meta-regression analysis indicate that the association does not vary by age (OR 0.97 [0.92, 1.02], p = 0.244), male (OR 1.05 [0.99, 1.11], p = 0.091), hypertension (OR 9.98 [0.95, 1.02], p = 0.317), diabetes (OR 0.99 [0.93, 1.05], p = 0.699), chronic kidney disease (OR 1.01 [0.93, 1.10], p = 0.756), non-steroidal anti-inflammatory drug use (OR 1.02 [0.96, 1.09], p = 0.499), and pre-admission/in-hospital PPI use (OR 0.77 [0.26, 2.31], p = 0.644). PPI use was not associated with the susceptibility to COVID-19 (OR 1.56 [0.48, 5.05], p = 0.46; I2 99.7%).
CONCLUSION: This meta-analysis showed a potential association between PPI use and composite poor outcome, but not susceptibility.
PROSPERO ID: CRD42020224286.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Pharmacological reports : PR - 73(2021), 6 vom: 10. Dez., Seite 1642-1649 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pranata, Raymond [VerfasserIn] |
---|
Links: |
---|
Themen: |
Coronavirus |
---|
Anmerkungen: |
Date Completed 30.11.2021 Date Revised 30.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s43440-021-00263-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM323951236 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323951236 | ||
003 | DE-627 | ||
005 | 20231225185258.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s43440-021-00263-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1079.xml |
035 | |a (DE-627)NLM323951236 | ||
035 | |a (NLM)33840053 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pranata, Raymond |e verfasserin |4 aut | |
245 | 1 | 0 | |a Proton pump inhibitor on susceptibility to COVID-19 and its severity |b a systematic review and meta-analysis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.11.2021 | ||
500 | |a Date Revised 30.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. Maj Institute of Pharmacology Polish Academy of Sciences. | ||
520 | |a BACKGROUND: The negative impacts of proton pump inhibitor (PPI), including the risk of pneumonia and mortality, have been reported previously. This meta-analysis aimed to address the current interest of whether the administration of PPI could increase the susceptibility and risk of poor outcome in COVID-19 | ||
520 | |a METHODS: We performed a systematic literature search from PubMed, Embase, EBSCOhost, and EuropePMC databases up until 3 December 2020. The main outcome was composite poor outcome which comprised of mortality and severe COVID-19. Severe COVID-19 in this study was defined as patients with COVID-19 that fulfill the criteria for severe CAP, including the need for intensive unit care or mechanical ventilation. The secondary outcome was susceptibility, based on cohort comparing COVID-19 positive and COVID-19 negative participants | ||
520 | |a RESULTS: There were a total of 290,455 patients from 12 studies in this meta-analysis. PPI use was associated with increased composite poor outcome (OR 1.85 [1.13, 3.03], p = 0.014; I2 90.26%). Meta-regression analysis indicate that the association does not vary by age (OR 0.97 [0.92, 1.02], p = 0.244), male (OR 1.05 [0.99, 1.11], p = 0.091), hypertension (OR 9.98 [0.95, 1.02], p = 0.317), diabetes (OR 0.99 [0.93, 1.05], p = 0.699), chronic kidney disease (OR 1.01 [0.93, 1.10], p = 0.756), non-steroidal anti-inflammatory drug use (OR 1.02 [0.96, 1.09], p = 0.499), and pre-admission/in-hospital PPI use (OR 0.77 [0.26, 2.31], p = 0.644). PPI use was not associated with the susceptibility to COVID-19 (OR 1.56 [0.48, 5.05], p = 0.46; I2 99.7%) | ||
520 | |a CONCLUSION: This meta-analysis showed a potential association between PPI use and composite poor outcome, but not susceptibility | ||
520 | |a PROSPERO ID: CRD42020224286 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Coronavirus | |
650 | 4 | |a Gastrointestinal | |
650 | 4 | |a Infection rate | |
650 | 4 | |a Proton pump inhibitor | |
650 | 4 | |a Severity | |
650 | 4 | |a Susceptibility | |
650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
700 | 1 | |a Huang, Ian |e verfasserin |4 aut | |
700 | 1 | |a Lawrensia, Sherly |e verfasserin |4 aut | |
700 | 1 | |a Henrina, Joshua |e verfasserin |4 aut | |
700 | 1 | |a Lim, Michael Anthonius |e verfasserin |4 aut | |
700 | 1 | |a Lukito, Antonia Anna |e verfasserin |4 aut | |
700 | 1 | |a Kuswardhani, Raden Ayu Tuty |e verfasserin |4 aut | |
700 | 1 | |a Wibawa, I Dewa Nyoman |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 73(2021), 6 vom: 10. Dez., Seite 1642-1649 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2021 |g number:6 |g day:10 |g month:12 |g pages:1642-1649 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-021-00263-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 73 |j 2021 |e 6 |b 10 |c 12 |h 1642-1649 |